Clinical Trial Update: Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results evaluate MEDI-551 (inebilizumab) in combination with immunomodulating therapies for relapsed or refractory aggressive B-cell lymphoma; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Or Refractory Aggressive B-cell Lymphoma

Drugs mentioned

• MEDI-551 (inebilizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Relapsed/Refractory Aggressive B-cell Lymphomas | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-03-12